Elvia Cowan, who serves as senior vice president, finance and chief accounting officer at Vaxcyte, Inc. (NASDAQ: PCVX), reported the sale of 1,892 shares of the companys common stock on March 17, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The total proceeds from the transactions were approximately $105,146. The disposition was executed in two separate trades. The first tranche comprised 1,487 shares at a weighted-average price of $55.387, with individual sale prices ranging from $54.98 to $55.935. The second tranche comprised 405 shares at a weighted-average price of $56.263, with prices in that block ranging from $56.00 to $56.42.
Following these sales, Cowan retained direct ownership of 28,975 shares of Vaxcyte common stock. The Form 4 filing notes the transactions were carried out pursuant to a Rule 10b5-1 trading plan that was adopted on December 8, 2025.
Vaxcytes shares were trading around $54.29 at the time of reporting, a level that corresponds to a market capitalization of about $7.8 billion. An InvestingPro analysis included in the filing commentary characterizes the shares as slightly undervalued at current levels. An InvestingPro Tip also notes the company appears to hold more cash than debt on its balance sheet, a detail that indicates a relatively strong liquidity position for the biotech firm.
Corporate financing activity has been prominent for Vaxcyte in recent months. The company closed a public offering that generated $632.5 million in gross proceeds, achieved through the sale of 12,650,000 common shares at $50.00 apiece, including the full exercise of the underwriters option to purchase additional shares. In a separate, related transaction, Vaxcyte priced another public offering expected to bring in $550 million in gross proceeds, with that deal scheduled to close in early February 2026.
Analysts covering Vaxcyte have expressed favorable views in light of the companys regulatory positioning and product pipeline. Jefferies reiterated a Buy rating and set a price target of $146.00, citing regulatory clarity. BTIG also maintained a Buy rating while raising its price target to $89, and highlighted the competitive position of Vaxcytes vaccine candidate, VAX-31. Leerink Partners lifted its price target to $82, noting expansion of the companys vaccine pipeline and plans to advance VAX-A1 into Phase 1 trials.
These analyst endorsements and the recent capital raises underscore Vaxcytes ongoing strategic efforts to support development of its vaccine candidates and to bolster financial resources. The insider sale by Cowan, executed under a pre-established 10b5-1 plan, represents a relatively modest transaction compared with the scale of the companys recent equity financings and balance sheet totals.
Data snapshot
- Insider: Elvia Cowan, SVP, Finance & CAO
- Date of sale: March 17, 2026
- Shares sold: 1,892
- Proceeds: Approximately $105,146
- Post-sale direct holdings: 28,975 shares
- Trading plan: Rule 10b5-1 adoption date December 8, 2025
- Recent financings: $632.5 million closed offering; $550 million offering priced to close early February 2026